Grandfield & Dodd’s Eledon Pharmaceuticals ELDN Stock Holding History

Grandfield & Dodd’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.4K	Hold	10,000	–	–	﹤0.01%	216
2026 Q1	$30.8K	Buy	+10,000	New	+$23.6K	﹤0.01%	208

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Grandfield & Dodd's ELDN Position: Q2 2026 in Review

Grandfield & Dodd held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 10,000 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #216.

Grandfield & Dodd first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Grandfield & Dodd held 10,000 shares of Eledon Pharmaceuticals worth $39.4K as of Q2 2026.
Grandfield & Dodd left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Grandfield & Dodd's portfolio in Q2 2026, its #216 holding.
Grandfield & Dodd first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.